Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.

Wataru FukuokayaTakahiro KimuraTakafumi YanagisawaShoji KimuraShunsuke TsuzukiYuhei KoikeYuya IwamotoYuki EneiMasatoshi TanakaFumihiko UrabeHajime OnumaMariko HondaJun MikiYu OyamaHirokazu AbeShin Egawa

Published in: Cancer immunology, immunotherapy : CII (2021)

Continued pembrolizumab administration beyond progression might be beneficial in patients with metastatic UC who were clinically stable.

Keyphrases

advanced non small cell lung cancer
tyrosine kinase